Robert A. Wermers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert A. Wermers has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Ann E. Kearns
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine (M.L.G., A.E.K., R.A.W.)
4 shared publicationsEuijung Ryu
Divisions of Biomedical Statistics and Informatics (E.R., P.T., M.A.H.) Rochester, Minnesota 55905
3 shared publications- Geoffrey B. Thompson
Department of Surgery, Mayo Clinic, Rochester, MN, USA
3 shared publications L. Joseph Melton
Epidemiology (L.J.M.), Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905
3 shared publicationsMarcio L. Griebeler
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine (M.L.G., A.E.K., R.A.W.) 4 Sanford University of South Dakota Medical Center (M.L.G.), Sioux Falls, South Dakota 57117
3 shared publications- Ann E. Kearns
Mayo College of Medicine, Mayo Clinic
2 shared publications
Latest Publications
- 30 April 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 41 (11) , 1151-1152
Validating fracture risk after stoke: a call to action to optimize skeletal health after stroke?
- 30 April 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 41 (11) , 1151-1152
Validating fracture risk after stoke: a call to action to optimize skeletal health after stroke?
- Open Access
- 23 February 2024
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 2 (3) , luae022
Efficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D
Elevated 1,25-dihydroxyvitamin D (1,25(OH)2D) is a rare cause of non–parathyroid hormone (PTH)–mediated hypercalcemia seen in granulomatous disease, malignancy (most often lymphoma), or genetic mutations. Therapeutic options are limited. We report the case of a 67-year-old White man with nonmalignant, nongranulomatous, 1,25(OH)2D-mediated hypercalcemia treated successfully with cinacalcet. At presentation, he had hypercalcemia, hypercalciuria with recurrent nephrolithiasis, low PTH, elevated 1,25(OH)2D, and normal 25-hydroxyvitamin D. The 1,25(OH)2D levels were inappropriate in the setting of hypercalcemia with low PTH. Evaluations for sarcoidosis, tuberculosis, and malignancy were negative. Genetic testing showed biallelic variants in the CYP24A1 gene. Cinacalcet was trialed and showed normalization of calcium levels. On cinacalcet, biochemical indices showed a slight increase in 1,25(OH)2D and 24-hour urine calcium and mild decrease in PTH. He briefly experienced symptomatic hypocalcemia that resolved after reducing cinacalcet dose. Due to limited symptomatic benefit, he opted to stop cinacalcet. Additional follow-up showed intermittently elevated serum calcium levels after stopping cinacalcet, most recently 10.3 mg/dL. Cinacalcet may be a therapeutic option in nonmalignant, 1,25(OH)2D-mediated hypercalcemia. Further study is necessary to confirm efficacy, understand risks and benefits, and elucidate mechanism(s) of action.
- 23 February 2024
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 2 (3) , luae022
Open AccessEfficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D
Elevated 1,25-dihydroxyvitamin D (1,25(OH)2D) is a rare cause of non–parathyroid hormone (PTH)–mediated hypercalcemia seen in granulomatous disease, malignancy (most often lymphoma), or genetic mutations. Therapeutic options are limited. We report the case of a 67-year-old White man with nonmalignant, nongranulomatous, 1,25(OH)2D-mediated hypercalcemia treated successfully with cinacalcet. At presentation, he had hypercalcemia, hypercalciuria with recurrent nephrolithiasis, low PTH, elevated 1,25(OH)2D, and normal 25-hydroxyvitamin D. The 1,25(OH)2D levels were inappropriate in the setting of hypercalcemia with low PTH. Evaluations for sarcoidosis, tuberculosis, and malignancy were negative. Genetic testing showed biallelic variants in the CYP24A1 gene. Cinacalcet was trialed and showed normalization of calcium levels. On cinacalcet, biochemical indices showed a slight increase in 1,25(OH)2D and 24-hour urine calcium and mild decrease in PTH. He briefly experienced symptomatic hypocalcemia that resolved after reducing cinacalcet dose. Due to limited symptomatic benefit, he opted to stop cinacalcet. Additional follow-up showed intermittently elevated serum calcium levels after stopping cinacalcet, most recently 10.3 mg/dL. Cinacalcet may be a therapeutic option in nonmalignant, 1,25(OH)2D-mediated hypercalcemia. Further study is necessary to confirm efficacy, understand risks and benefits, and elucidate mechanism(s) of action.
- Open Access
- 12 May 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (12) , e1749-e1750
Incidence of Primary Hyperparathyroidism in the Current Era: Have We Finally Reached a Steady State?
The epidemiology of primary hyperparathyroidism (PHPT) has changed substantially since initial reports demonstrating classic complications in severe disease. Th
- 12 May 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (12) , e1749-e1750
Open AccessIncidence of Primary Hyperparathyroidism in the Current Era: Have We Finally Reached a Steady State?
The epidemiology of primary hyperparathyroidism (PHPT) has changed substantially since initial reports demonstrating classic complications in severe disease. Th
- Open Access
- 26 January 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (4) , bvad013
The Eucalcemic Patient With Elevated Parathyroid Hormone Levels
Primary hyperparathyroidism (PHPT) is classically characterized by hypercalcemia with elevated or inappropriately normal parathyroid hormone (PTH) levels. Elevated PTH levels in the presence of normal calcium levels are not infrequently found during the evaluation of metabolic bone disorders or kidney stone disease. This can be caused by secondary hyperparathyroidism (SHPT) or normocalcemic primary hyperparathyroidism (NPHPT). NPHPT is due to autonomous parathyroid function whereas SHPT is caused by a physiologic stimulation to PTH secretion. Many medical conditions and medications can contribute to SHPT, and differentiation between SHPT and NPHPT may be difficult. Cases are presented to illustrate examples. In this paper, we review the distinction between SHPT and NPHPT as well as end organ effects of NPHPT and outcomes of surgery in NPHPT. We suggest that the diagnosis of NPHPT be made only after careful exclusion of causes of SHPT and consideration of medications that can increase PTH secretion. Further, we advise a conservative approach to surgery in NPHPT.
- 26 January 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (4) , bvad013
Open AccessThe Eucalcemic Patient With Elevated Parathyroid Hormone Levels
Primary hyperparathyroidism (PHPT) is classically characterized by hypercalcemia with elevated or inappropriately normal parathyroid hormone (PTH) levels. Elevated PTH levels in the presence of normal calcium levels are not infrequently found during the evaluation of metabolic bone disorders or kidney stone disease. This can be caused by secondary hyperparathyroidism (SHPT) or normocalcemic primary hyperparathyroidism (NPHPT). NPHPT is due to autonomous parathyroid function whereas SHPT is caused by a physiologic stimulation to PTH secretion. Many medical conditions and medications can contribute to SHPT, and differentiation between SHPT and NPHPT may be difficult. Cases are presented to illustrate examples. In this paper, we review the distinction between SHPT and NPHPT as well as end organ effects of NPHPT and outcomes of surgery in NPHPT. We suggest that the diagnosis of NPHPT be made only after careful exclusion of causes of SHPT and consideration of medications that can increase PTH secretion. Further, we advise a conservative approach to surgery in NPHPT.
- 1 January 2022
- Published by Springer Nature
- p. 209-222
Medication-Induced Hypercalcemia
- 1 July 2020
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (1) , 127-131
Rates of hypercalcemia and hyperparathyroidism among patients with porcelain gallbladder
- 1 July 2020
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (1) , 127-131
Rates of hypercalcemia and hyperparathyroidism among patients with porcelain gallbladder
- Open Access
- 1 December 2019
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 35 (4) , 662-670
Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations
Inactivating mutations of the ENPP1 gene are associated with generalized arterial calcification of infancy (GACI) and less often autosomal‐recessive hypophosphatemic rickets type 2 (ARHR2). We aimed to investigate the spectrum of phenotypes in a family with monoallelic and biallelic mutations of ENPP1 after identification through whole exome sequencing of a 54‐year‐old female with biallelic mutation of ENPP1, c.323G > T; p.Cys108Phe and c.1441C > T; p.Arg481Trp. Including the proband, 2 subjects had biallelic mutations, 5 had monoallelic mutations, and 2 had no mutation of ENPP1. The maternal mutation, a known pathogenic variant associated with GACI, was found in 3 subjects with monoallelic mutations, while the paternal mutation, which was not previously reported, was present in 2 subjects with monoallelic mutations. Both subjects with biallelic mutations had bowing of bilateral femurs, periarticular mineral deposition, normocalcemic primary hyperparathyroidism with multigland parathyroidectomy, increased carotid intima‐media thickness, and enthesopathy was also noted in one subject. Intact FGF23 was elevated in both subjects with biallelic mutations, while C‐terminal FGF23 was only elevated in one and PPi was reduced in one. Subjects with monoallelic mutations did not have periarticular calcifications or bone deformities. To conclude, patients with biallelic GACI causing mutations can survive well into adulthood, and despite the same biallelic ENPP1 pathogenic variants, clinical and biochemical manifestations can significantly differ, and include enthesopathy and primary hyperparathyroidism, which have not been previously described. Although carriers of monoallelic ENPP1 variants appear unaffected by classic disease manifestations, there may be subtle biochemical and clinical findings that warrant further investigation. © 2019 American Society for Bone and Mineral Research.
- 1 December 2019
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 35 (4) , 662-670
Open AccessClinical and Biochemical Phenotypes in a Family With ENPP1 Mutations
Inactivating mutations of the ENPP1 gene are associated with generalized arterial calcification of infancy (GACI) and less often autosomal‐recessive hypophosphatemic rickets type 2 (ARHR2). We aimed to investigate the spectrum of phenotypes in a family with monoallelic and biallelic mutations of ENPP1 after identification through whole exome sequencing of a 54‐year‐old female with biallelic mutation of ENPP1, c.323G > T; p.Cys108Phe and c.1441C > T; p.Arg481Trp. Including the proband, 2 subjects had biallelic mutations, 5 had monoallelic mutations, and 2 had no mutation of ENPP1. The maternal mutation, a known pathogenic variant associated with GACI, was found in 3 subjects with monoallelic mutations, while the paternal mutation, which was not previously reported, was present in 2 subjects with monoallelic mutations. Both subjects with biallelic mutations had bowing of bilateral femurs, periarticular mineral deposition, normocalcemic primary hyperparathyroidism with multigland parathyroidectomy, increased carotid intima‐media thickness, and enthesopathy was also noted in one subject. Intact FGF23 was elevated in both subjects with biallelic mutations, while C‐terminal FGF23 was only elevated in one and PPi was reduced in one. Subjects with monoallelic mutations did not have periarticular calcifications or bone deformities. To conclude, patients with biallelic GACI causing mutations can survive well into adulthood, and despite the same biallelic ENPP1 pathogenic variants, clinical and biochemical manifestations can significantly differ, and include enthesopathy and primary hyperparathyroidism, which have not been previously described. Although carriers of monoallelic ENPP1 variants appear unaffected by classic disease manifestations, there may be subtle biochemical and clinical findings that warrant further investigation. © 2019 American Society for Bone and Mineral Research.
- 1 July 2019
- Published by Elsevier in Endocrine Practice
- Vol. 25 (7) , 648-656
Transient Osteoporosis: Clinical Spectrum in Adults and Associated Risk Factors
- 1 July 2019
- Published by Elsevier in Endocrine Practice
- Vol. 25 (7) , 648-656
Transient Osteoporosis: Clinical Spectrum in Adults and Associated Risk Factors
- Open Access
- 1 March 2018
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 4 (2) , 98-103
Skeletal Fluorosis Related to Habitual Tea Consumption: Long-Term Follow-Up After Reduction and Discontinuation of Tea
- 1 March 2018
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 4 (2) , 98-103
Open AccessSkeletal Fluorosis Related to Habitual Tea Consumption: Long-Term Follow-Up After Reduction and Discontinuation of Tea